NY-ESO-1 expression in sarcomas

[D.ap]

NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.

Keywords: NY-ESO-1, T-cell receptor, cancer-testis antigen, clinical trial, diagnostic marker, immunotherapy, melanoma, sarcomas, synovial sarcoma, therapeutic target

We found that 76% of synovial sarcomas expressed NY-ESO-1 in a strong and diffuse pattern (2–3+, > 50–70% of tumor cells). In contrast, only rare cases of other spindle cell mesenchymal tumor expressed NY-ESO-1: GIST (2/155), malignant peripheral nerve sheath tumors (1/34), and dermatofibrosarcoma protuberans (2/20). Individual cases of other sarcomas (angiosarcoma, malignant mesothelioma, chondrosarcoma, osteosarcoma, dedifferentiated liposarcoma, alveolar soft part sarcoma, and Ewing's sarcoma) were positive for NY-ESO-1
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518519/

[D.ap]

Un fortunately subsets are shown as a minute expression
Statistically we are a little representative of the big picture

[D.ap]

Does low mitopic = low levels ?

[D.ap]

http://www.cureasps.org/forum/viewtopic.php?f=2&t=1207

[Olga]

At some point we sent Ivan's tumor tissue sample for testing and his was tested negative for NY-ESO-1 (it was a slice from the lung met, as I understand the problem is that there is often a big heterogeneity in genes expression between the primary and mets and also depends on the location in the body and also the expression in the same tumor changes as the time goes - the tumor mutates).

[D.ap]

Hello Olga and Ivan

In reference to test on the lung tumor for the NY-ESO-1 antigen , how was that performed ? Was it performed in Germany after his laser lung surgery ? What year was the test performed, approximately ?

Also , Ivan’s primary tumor was in his arm? And was less than 2cm? At the age of 17?

Thanks in advance
Debbie

[Olga]

Debbie, there was a promising trial for sarcomas expressing this marker in US - I knew someone with synovial sarcoma having a very good response on the trial (unfortunately she eventually developed a resistance after couple of years being almost NED), subject to presenting tumor blocks and testing them as positive as an enrollment condition. I had the blocks from Germany surgery and sent them, they were tested negative.
Ivan was Dx in 2003, 17 years old, 18 mm primary in the right arm.

[D.ap]

Thank you Olga
I wonder if the primary would of brought different
results ?
The driver of the mutation(s) to the lungs? Verses the passenger(s) mets , in the lungs ?

The testing appears to be fairly accurate in its results however if the mets in the lungs didn’t have the same original mutations , of the primary , the CTA and or the NY-ESO-1 expressions may of not been within detectable range , as you so graciously pointed out in 2016. : )

http://www.cureasps.org/forum/viewtopic ... 1975#p9026